Bringing hope and life-changing therapies to patients & their families
We develop therapies for patients with rare diseases
Our Phase 3 PolarisDMD clinical trial with edasalonexent in muscular dystrophy is ongoing.
September 8, 2020: Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences
September 2, 2020: Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy
August 10, 2020: Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress
We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination.
A potential foundational therapy aimed at improving the lives of all affected by Duchenne.
Join Our Team